{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:11Z","timestamp":1784945831494,"version":"3.55.0"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>Chronic kidney disease (CKD) and cardiovascular disease are intimately linked. They share major risk factors, including age, hypertension, and diabetes, and common pathogenetic mechanisms. Furthermore, reduced renal function and kidney injury documented with albuminuria are independent risk factors for cardiovascular events and mortality. In major renal outcome trials and subsequent meta-analyses in patients with CKD, ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin II receptor blockers) were shown to effectively retard CKD progression but not to significantly reduce cardiovascular events or mortality. Thus, a high residual risk for cardiovascular disease progression under standard-of-care treatment is still present for patients with CKD. In contrast to the above, several outcome trials with SGLT-2 (sodium-glucose cotransporter-2) inhibitors and MRAs (mineralocorticoid receptor antagonists) clearly suggest that these agents, apart from nephroprotection, offer important cardioprotection in this population. This article discusses existing evidence on the effects of SGLT-2 inhibitors and MRAs on cardiovascular outcomes in patients with CKD that open new roads in cardiovascular protection of this heavily burdened population.<\/jats:p>","DOI":"10.1161\/hypertensionaha.121.17005","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T09:00:36Z","timestamp":1617008436000},"page":"1442-1455","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease"],"prefix":"10.1161","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":true,"given":"Pantelis","family":"Sarafidis","sequence":"first","affiliation":[{"name":"Department of Nephrology (P.S.), Aristotle University of Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-9066","authenticated-orcid":true,"given":"Christodoulos E.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Third Department of Cardiology (C.E.P.), Aristotle University of Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Kamperidis","sequence":"additional","affiliation":[{"name":"Hippokration Hospital and First Department of Cardiology, AHEPA Hospital (V.K., G.G.), Aristotle University of Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-6319","authenticated-orcid":true,"given":"George","family":"Giannakoulas","sequence":"additional","affiliation":[{"name":"Hippokration Hospital and First Department of Cardiology, AHEPA Hospital (V.K., G.G.), Aristotle University of Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine (M.D.), Aristotle University of Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.17.2038"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.07.012"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60178-5"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.09.003"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.48"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_3_4_9_2","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910975"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012749"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017020148"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa015"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001940"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2719"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208799"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303154"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666191029111713"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy407"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa198"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.12.006"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.355"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2012.04.001"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2421"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2008.206"},{"key":"e_1_3_4_36_2","first-page":"CD007751","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.","author":"Sharma P","year":"2011","unstructured":"Sharma, P, Blackburn, RC, Parke, CL, McCullough, K, Marks, A, Black, C. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011;CD007751.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2016.1165065"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188975"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001283"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001657"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs590"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0605-7"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.52"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.046"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.02.022"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2004861"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/1470320312439140"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0575"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.86"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2019.1624721"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1083977"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.06.010"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1087"},{"key":"e_1_3_4_54_2","unstructured":"Forxiga\u00ae. Summary of Product Characteristics. 2012 [Internet]. Accessed October 19 2020. https:\/\/www.ema.europa.eu\/documents\/product-information\/forxiga-epar-product-information_en.pdf"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2018-0514"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000719"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1201073"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.06.017"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-00393-4"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028268"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035901"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051901"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.14901219"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051685"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10140620"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051675"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019111168"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa234"},{"key":"e_1_3_4_78_2","unstructured":"U.S. National Library of Medicine. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) [Internet]. Accessed October 19 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03594110"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy090"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8871-2_15"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-0386-5"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190306162658"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573402115666190415155512"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002187"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1400"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.056"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12628"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12718"},{"key":"e_1_3_4_94_2","unstructured":"University Hospital Brest. ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST) Phase III b [Internet]. clinicaltrials.gov; 2020. Accessed February 11 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01848639"},{"key":"e_1_3_4_95_2","unstructured":"Population Health Research Institute. Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease [Internet]. clinicaltrials.gov; 2020. Accessed February 11 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03020303"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1159\/000503713"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1159\/000503712"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa294"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.121.17005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:30:20Z","timestamp":1715596220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.121.17005"}},"subtitle":["A Milestone Achieved"],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.121.17005"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.121.17005","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2021-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}